Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 2, 2026, Esperion Therapeutics, Inc. (the “Company”) entered into an Agreement
, including the Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende
. Financial Statements and Exhibits. Exhibit No. Description 2.1 Agreement and Plan of Merger, dated as of March 2, 2026, by and among Esperion Therapeutics, In